Bladder Cancer Panel +3,+7,+17,9p21-
Expected Turnaround Time
5 days
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Stated turn-around-times (TATs) are for clinical use only and subject to change based on biopharma protocol requirements. Final TATs will be specified in the biopharma study contract.
Clinical Information
FISH panel test on urine specimens for the detection and monitoring of patients suspected of having bladder cancer. Includes probes to detect gains of chromosomes 3, 7, and 17, and loss of the p-arm of chromosome 9. The FDA-approved Vysis Urovysion Bladder Cancer assay can be performed upon request.
Requisition Forms
Specimen Requirements
Specimen Requirements
Voided urine must be > 33 mL. Mix voided urine with preservative at 2:1 ratio of urine to preservative (PreservCyt® or Carbowax® solutions) for a total volume > 50 mL.
Specimen Stability
72 hours
Storage Requirements
Urine: 2°C to 8°C
Fixed Cytogenetically Prepared Cells: -28°C to -15°C
Shipping Conditions
Refrigerated
Shipping Recommendations
REFRIGERATED, Protect from extreme temperature with ice pack. Separate ice pack from specimen. Do not freeze.
Specimen Rejection Criteria
Any non-urine specimen including bladder or renal pelvic washings; Incorrect preservative; Sample exposed to extreme temperature; Insufficient volume or number of cells for analysis; Specimen transport greater than 48 hours
Test Details
Synonyms
+3,+7,+17, del(9)(p21)
Keywords
Fluorescence in-situ Hybridization, Oncology, Bladder Cancer, Oncology FISH Panels
Test Method
Fluorescence in situ hybridization (FISH)
Methodology Category
FISH
Regulatory Status
ASR
Associations
Bladder Cancer